Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalDRTS +14.06%28 Debt-to-Equity is 0.21 as of Mar. 2026, which is 24% above its 10-year median of 0.17. GuruFocus rates DRTS with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 967 Biotechnology companies, Alpha Tau Medical ranks worse than 55.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Alpha Tau Medical's Debt-to-Equity or its related term are showing as below:
DRTS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.17 Max: 0.22
Current: 0.21
During the past 7 years, the highest Debt-to-Equity Ratio of Alpha Tau Medical was 0.22. The lowest was 0.05. And the median was 0.17.
DRTS's Debt-to-Equity is ranked worse than 55.84% of 967
companies
in the Biotechnology industry
Industry Median: 0.16
vs DRTS: 0.21
Alpha Tau Medical (NAS:DRTS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Alpha Tau Medical Debt-to-Equity Related Terms
Alpha Tau Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRTS vs ORIC, OLMA, KURA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Alpha Tau Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTS) has a Debt-to-Equity of 0.21 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alpha Tau Medical and its competitors. This is 24% above median its historical median of 0.17. Over the past decade, Alpha Tau Medical's Debt-to-Equity has ranged from 0.05 to 0.22. According to the industry distribution chart, Alpha Tau Medical ranks #540 out of 967 companies in the Biotechnology industry, placing it in the top 55.8%.
Is Alpha Tau Medical's Debt-to-Equity too high?
Alpha Tau Medical's current Debt-to-Equity of 0.21 is 24% above median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 0.22. The Biotechnology industry median Debt-to-Equity is 0.16. Alpha Tau Medical's value of 0.21 is 31.3% above this industry median. Based on the distribution chart, Alpha Tau Medical ranks #540 out of 967 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Debt-to-Equity compare to ORIC and OLMA?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #540 out of 967 companies for Debt-to-Equity. This places Alpha Tau Medical in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Alpha Tau Medical's value of 0.21 is 31.3% above this benchmark. Historically, Alpha Tau Medical's own Debt-to-Equity has ranged from 0.05 to 0.22 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 0.16, Alpha Tau Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Tau Medical's current Debt-to-Equity of 0.21 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Alpha Tau Medical and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current Debt-to-Equity is 0.21, which is 24% above median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Debt-to-Equity of 0.21. The current Debt-to-Equity is 0.21, which is 24% above median its 10-year median of 0.17 and 31.3% above the Biotechnology industry median of 0.16. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Debt-to-Equity is 0.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
